Our study findings highlighted the complexity of genetic influences on drug responses, particularly the absence of significant associations between specific SLCO1B3 polymorphisms and MTX efficacy and safety treatment in RA. This evidence concerns the gene SLCO1B3 and rheumatoid arthritis.